Home / 2021 / July / 20

Daily Archives: July 20, 2021

WillScot Mobile Mini Holdings to Announce Second Quarter 2021 Results on August 5, 2021

PHOENIX, July 20, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corporation (Nasdaq: WSC) today announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021 after the markets close.

Chief Executive Officer, Brad Soultz and Chief Financial Officer, Tim Boswell will host a conference call and webcast on Friday, August 6, 2021 at 10:00 a.m. EDT to discuss the results.

The live call can be accessed by dialing (855) 312-9420 (US/Canada toll-free) or (210) 874-7774 (International). A live webcast will also be accessible via the “Events & Presentations” section of the company’s website www.willscotmobilemini.com. An archived version of the webcast will be available for 60 days following the call.

About WillScot Mobile Mini Holdings

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 275 branch locations and additional drop lots throughout the United States, Canada, Mexico, and the United Kingdom.

Additional Information and Where to Find It

Additional information can be found on the company’s website at www.willscotmobilemini.com

Contact Information

Investor Inquiries:

Nick Girardi
[email protected]willscotmobilemini.com

Media Inquiries:

Scott Junk
[email protected]com

Eyenuk Announces $6.2 Million Financing to Accelerate Adoption of FDA-cleared AI Technology for Detection of Diabetic Retinopathy

Financing led by AXA IM’s Impact Investing strategy

LOS ANGELES, July 20, 2021 (GLOBE NEWSWIRE) — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, today announced that it has completed a financing round of US$6.2 million led by AXA IM, through AXA IM Alts, a global leader in alternative investments with c. €162 billion of assets under management1. Eyenuk’s existing investors also participated in the round.

Eyenuk will use the proceeds to immediately accelerate commercialization of the EyeArt® AI System, which received FDA clearance in 2020 and is being reimbursed by Medicare and other payors.

AXA IM Alts’ investment in Eyenuk is advised by Dr. Zina Affas Besse, Managing Partner at Global Health Investment Advisors (GHIA), a pioneer in impact investing in life science companies. “We are very impressed with all that the Eyenuk team has accomplished to date,” said Dr. Affas Besse. “We look forward to supporting the company as it accelerates global commercialization and pipeline development programs.”

“We are excited about Eyenuk’s business potential as evidenced by Eyenuk’s impressive business and clinical accomplishments to-date,” said Jonathan Dean, Head of Impact Investing at AXA IM Alts. “We are proud to invest in some of the most innovative technologies that address major public health issues worldwide, while searching to generate attractive social and financial returns. Eyenuk’s innovative healthcare AI technologies aim to deliver tangible impact around the world alongside attractive financial returns.”

“We are thrilled to welcome new institutional investors to the Eyenuk team,” said Kaushal Solanki, Ph.D., Founder and CEO of Eyenuk. “We look forward to working with AXA IM Alts and other investors, who share Eyenuk’s vision of creating globally-accessible AI platform technology that can enable drastic reduction of preventable blindness across the world.”

Eyenuk plans to close a larger round of financing in late 2021 to support its long-term growth and innovation strategies.

About the EyeArt AI System
The EyeArt AI System provides fully automated DR screening, including retinal imaging, DR detection based on international clinical standards and immediate reporting, in a single office visit during a diabetic patient’s regular exam. Once the patient’s fundus images have been captured and submitted to the EyeArt AI System, the DR detection results are available in a PDF report in less than 30 seconds.

The EyeArt AI System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). In addition to US FDA 510(k) clearance, the EyeArt AI System has CE marking as a class 2a medical device in the European Union and a Health Canada license. It is designed to be General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.

EyeArt is reimbursed by government and private payors in the U.S. under the newly created Current Procedural Terminology (CPT) code 92229. Medicare started its national coverage for CPT 92229 on January 1, 2021.

VIDEO: Learn more about the EyeArt AI System for Autonomous Detection of Diabetic Retinopathy

About Eyenuk, Inc.
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease. Find Eyenuk online on its website, Twitter, Facebook, and LinkedIn.

About AXA IM’s approach to impact investing
AXA IM manages a variety of impact strategies, ranging from private equity investments to green and social bonds and listed equities and bonds, which look to provide solutions relating to issues such as healthcare, climate change and biodiversity.

AXA IM’s impact range is its most focused responsible investment offering, with products specifically designed to have a direct, measurable and positive impact on society and/or the environment. These strategies will report definitive and measurable data against impact KPIs such as carbon footprint or lives improved, and each will target one or more UN SDGs. These strategies have a parallel commitment to deliver returns by tapping into the key themes of the sustainability economy. As of the end of March 2021, AXA IM managed about €2.6 billion of assets in this category. More information about AXA IM’s approach to impact investing here.

About AXA IM Alts 
AXA IM Alts is a global leader in alternative investments with €162 billion of assets under management1 as of 31 March 2021, across real assets (real estate & infrastructure), private debt & alternative credit and private equity & hedge funds. AXA IM Alts employs over 750 people located in 16 offices around the world and serves the needs of more than 350 clients from Europe, North America, Asia Pacific and Middle East. We are a global leader in real assets investment with c. €109 billion of assets under management, the number one property portfolio and asset manager in Europe2, and one of the largest worldwide.

Visit our websites https://realassets.axa-im.com and www.axa-im.com. Follow us on Twitter @AXAIMRealAssets and @AXAIM.

About Global Health Investment Advisors
Through its work as the investment manager for the Global Health Investment Fund and its partnership with AXA IM Alts, Global Health Investment Advisors has pioneered impact investing in life science companies. The firm seeks attractive financial returns and works with companies to facilitate the introduction of innovative products worldwide, including low-income countries. Its portfolio companies have generated compelling exits and have saved and improved millions of lives. Find GHIA online on its website.

Eyenuk, Inc. Contact
Frank Cheng, President & CCO
[email protected]
+1 818 835 3585

1 Source: AXA IM Alts unaudited data, as of March 2021.
2 Source: INREV Fund Manager Survey, June 2021. #1 largest European managers in total real estate assets under management.

Blue California Commercializes Nicotinamide Mononucleotide (NMN) for Supporting an Increased Healthspan

A better cost-effective option is now available for dietary supplement, functional food, and beverage manufacturers.

Rancho Santa Margarita, Calif., July 20, 2021 (GLOBE NEWSWIRE) — Blue California joins with the innovative Massachusetts-based biotech company Conagen to announce the commercialization of high-purity, fermentation-derived nicotinamide mononucleotide (NMN). A nature-based metabolic component which has caught the attention of health-conscious consumers for supporting energy and longevity.

The quest to age healthily and support longevity is surging among health-conscious consumers. “Consumers are reassessing their dietary regimen to make room for ingredients that can support an increased healthspan,” said Chief Science Officer at Blue California, Dr. Priscilla Samuel.

NMN supplements are highly sought-after for healthy aging applications, including brain health, vitality, heart health, metabolic health, and even cosmetics. However, current NMN ingredients used in products on the market are mostly produced by chemical synthesis.

While consumers are exploring dietary supplements for a holistic approach to health, they are also demanding clean labels from their supplements, and moving away from synthetic ingredients. Blue California’s fermentation-derived NMN opens new opportunities for producers to consider consumers’ health more holistically while acquiring a closer-to-nature position.

NMN serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme present in all living cells and critical for mitochondrial function.

Increased intracellular levels of NAD+ boost energy production and improve cellular health, but levels decline dramatically with age. Replenishing NAD+ in the body with its precursor NMN has been proposed as a way to possibly combat age-related degeneration and increase healthy lifespan.

“Our fermentation-derived offering is well-positioned to capitalize on the growing recognition of NMN as an important ingredient in the food and supplement spaces,” said Samuel. “NMN is a well-known molecule in the longevity research community, and emerging research also suggests potential applications for immune health as well as sports nutrition.”

Harvard professor David Sinclair, a well-recognized leader in the field of aging research, is an advocate of NMN for improving the health of aging populations.

“NMN is a logical extension to our line of “longevity ingredients” which includes ergothioneine and pyrroloquinoline quinone. All of these molecules are made by our own proprietary fermentation processes, enabling our customers to better serve consumers who might reject chemically-derived ingredients,” said VP of Innovation at Conagen, Dr. Casey Lippmeier. “Because of the way we make it, Conagen’s NMN is of the highest purity and quality.  It is also very cost-effective and compatible with clean-label trends, all of which demonstrates our strength as a strategic partner with Blue California.”

As innovation in dietary supplemental nutrition advances, so does the growth of global vitamin, mineral and supplement (VMS) launches. Mintel reported a growth of 67% of global VMS launches in Apr 2020 – Mar 2021, as compared to Apr 2016 – Mar 2017 — where the United States leads the VMS market.

About Blue California

Blue California is a vertically integrated technology company providing innovative ingredient solutions to global partners. With more than 20 years of innovation success, our ingredients are used in commercial products and applications in the industries of nutrition, personal care, healthy aging and wellness, functional food and beverage, and beauty. www.bluecal-ingredients.com

About Conagen

Conagen is making the impossible possible. Our scientists and engineers use the latest synthetic biology tools to develop high-quality sustainable nature-based products through systems of manufacturing on a molecular level and fermentation basis. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachment

Ana Arakelian
Blue California ingredients
+1-949-635-1991
[email protected]

Halfords Implements Descartes’ Last Mile Delivery Solution to Enable Dynamic Delivery Appointment Pricing in Mobile Service Business and as Part of New Avayler Field Service Software Platform

LONDON, July 20, 2021 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, has announced that UK-headquartered Halfords, a leading automotive products and services retailer, is using Descartes’ last mile delivery solution to enable dynamic delivery pricing in its customer-facing mobile tire replacement service and as its new international field service software solution called Avayler. First metrics show that Halford’s mobile service business has already been able to improve gross profit by 5% and reduce miles per delivery by 13%.

Descartes’ last mile delivery solution provides an end-to-end platform for home and last mile delivery operations. The solution spans delivery appointment booking, route planning and execution, mobile proof-of-delivery (POD) and notifications processes. Its delivery appointment schedule is dynamically generated for each customer and time window options are scored. This allows organizations such as Halfords to intelligently control the booking process, which maximizes booking density and productivity and enhances the customer experience while minimizing costs.

“As part of our innovative ecommerce-based mobile tire replacement service, we wanted to more accurately reflect the logistics cost of the mobile service when customers were booking service appointments and balance demand with our ability to serve customers,” said Chris McShane, Director, Strategy, Transformation & Business Development at Halfords. “Extending Descartes’ dynamic scheduling solution into Avayler made perfect sense. The solution will allow garages, distributors and other service-based organizations to provide their customer base with unique service appointment pricing as they are making purchases and the ability to optimize customer demand.”

The advanced real-time capabilities of the Descartes solution enable Halfords to offer dynamic delivery pricing that considers existing orders, business objectives, road network, vehicle capacity and service constraints to price delivery appointment options. In addition, Halfords uses Descartes’ forward-looking vehicle capacity information to help adjust its online marketing to ensure it balances demand generation with the ability to service that demand. As a result, Halfords has been able to target pay-per-click marketing spend by matching orders booked with the ability to service more customers in the coming days in particular regions.

After successfully using the Descartes last mile delivery solution to drive efficiencies in its own operations, Halfords has now integrated it into Avayler, its newly launched, end-to-end, customer-centric field service solution that will be rolled out globally. Avayler will provide other businesses with an end-to-end SaaS solution wherever they offer services whether in store, at garages, workshops, clinics, pop-up sites, in the driveway or across the threshold.

“By using logistics information and constraints in real-time during the customer buying experience, Halfords is taking last mile delivery strategies and solutions the next level,” said Pol Sweeney, Vice President of U.K. and Ireland Sales at Descartes. “Home and last mile delivery and services continue to be market differentiators, but expensive to operate. Halfords’ combination of our dynamic delivery appointment booking with its advanced pricing algorithms and capacity management allow the company to provide one of the most innovative and intuitive field service solutions on the market.”

About Halfords
Halfords is the U.K.’s leading retailer of motoring and cycling products and services. Through Halfords Autocentres, it is also one of the U.K.’s leading independent operators in vehicle servicing, maintenance and repairs. Headquartered in Redditch, West Midlands, Halfords employs nearly 10,000 colleagues up and down the country. For more information, visit www.halfords.com or contact:

Steve Marinker – +44 (0)7779 031 936
[email protected]group.com

Harold Amoo – +44 (0)7864 607 220
[email protected]com

About Descartes
Descartes (Nasdaq:DSGX) (TSX:DSG) is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, performance and security of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, schedule, track and measure delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world’s largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at www.descartes.com, and connect with us on LinkedIn and Twitter.

Global Media Contact
Cara Strohack
Tel: +1(800) 419-8495 ext. 202025
[email protected]

Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ solution offering and potential benefits derived therefrom including the ability to combine certain capabilities of Descartes with the proprietary systems of Halfords; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities commissions across Canada including Descartes most recently filed management’s discussion and analysis. If any such risks actually occur, they could materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines

SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.

Immorna’s unique mRNA construction and established versatile process platform are suitable for the development of self-replicating mRNA as well as conventional non-replicating mRNA products, enabling the construction of a customized form of mRNA molecule for a specific disease. In terms of delivery vehicles, Immorna has developed several nanoliposome particles (LNP) suitable for different administration methods and has technical capabilities in the field of research and development of new non-LNP delivery vehicles.

Under the terms of the agreement, Junshi Biosciences will inject at most 799 million RMB in cash into the joint venture. The initial investment is 200 million RMB, of which 50 million RMB will be used to subscribe to 50% of the registered capital of the joint venture. Immorna will invest in the joint venture company with intellectual property rights involved in the mRNA technology platform. The 50 million RMB in the estimated asset value of the platform will be used to subscribe to other 50% of the registered capital of the joint venture company.

“As the mRNA Technology Platform gradually matures, its potential in a variety of fields—including infectious diseases, cancer, rare diseases, and other diseases—has become increasingly evident,” says Dr. Ning Li, Chief Executive Officer of Junshi Biosciences. “This is highly consistent with the therapeutic areas covered by Junshi Biosciences’ R&D pipeline and our desire to explore the next generation of innovative therapeutics. Immorna has a wealth of experience and expertise in mRNA industrialization. We look forward to working together to develop more revolutionary therapeutics for patients worldwide through our mRNA Technology Platform with domestic intellectual property rights and promote public health on a global scale.”

“Immorna is very pleased to reach a strategic collaboration agreement with Junshi Biosciences, under which a joint venture company has been created,” says Dr. Zihao Wang, Chief Executive Officer of Immorna Therapeutics. “We are very confident that this new entity will allow us to take advantage of each other’s core competency, quickly and efficiently utilize the versatile mRNA platform technology in immunotherapy and infectious disease prevention, and continue our search for new directions of the application.”

About Immorna
Immorna is an innovative drug research company that focuses on developing self-replicating and conventional mRNA-based therapeutics and vaccines. It has maintained stable and fast growth since its incorporation in 2019. Currently, it has built a comprehensive set of mRNA synthesis, purification and analytical quality control processes well suited for commercial production and developed a common mRNA platform with higher expression levels (including self-replicating and non-self-replicating mRNA). With the aid of its efficient screening tools, Immorna has developed an arsenal of mRNA delivery vehicles including polymers and lipid nanoparticles. Immorna possesses multiple independent intellectual property rights applicable to cationic lipids suitable for intramuscular, intravenous or tissue-targeting delivery. Immorna has a diverse product pipeline spanning cancer immunotherapy, infectious diseases, rare genetic diseases and cosmetology. Immorna is quickly advancing its oncology and infectious disease projects into their clinical stages.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 28 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has received Emergency Use Authorization (EUA) from the US FDA in February 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at a high risk of progressing to severe COVID-19 and/or hospitalization. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Contact Information

IR Team:
Junshi Biosciences
[email protected]
+ 86 021-2250 0300

Solebury Trout
Bob Ai
[email protected]
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
[email protected]
+ 86 021-6105 8800

Swift Navigation และ KDDI ประกาศความร่วมมือเพื่อต่อยอดจากการขยายการระบุตำแหน่งที่แม่นยำทั่วโลก

ซานฟรานซิสโก, July 20, 2021 (GLOBE NEWSWIRE) — Swift Navigation บริษัทเทคโนโลยีในซานฟรานซิสโกกำลังสร้างนิยามใหม่ของ GNSS (ระบบนำทางด้วยดาวเทียมทั่วโลก) และเทคโนโลยีระบุตำแหน่งที่แม่นยำสำหรับยานพาหนะอัตโนมัติ ยานยนต์ แอปพลิเคชันมือถือและตลาดมวลชน วันนี้ได้ประกาศความร่วมมือกับ KDDI Corporation ซึ่งตั้งอยู่ในโตเกียว KDDI เป็นบริษัทโทรคมนาคมแนวหน้าระหว่างประเทศในการใช้นวัตกรรมเทคโนโลยีเพื่อให้บริการเครือข่ายที่มีคุณภาพและความน่าเชื่อถือสูง ที่สามารถตอบสนองความต้องการด้านการสื่อสารของลูกค้าทั่วโลก ความร่วมมือนี้จะเป็นสิ่งสำคัญในการนำเทคโนโลยีระบุตำแหน่งที่แม่นยำของ Swift ไปสู่ตลาดญี่ปุ่น และเพิ่ม KDDI เป็นพันธมิตรหลักในการขยายบริการระบุตำแหน่งที่แม่นยำของ Skylark ไปสู่ระดับโลก ซึ่งขณะนี้มีให้บริการทั่วทวีปสหรัฐอเมริกาและยุโรปภายใต้ความร่วมมือกับ Deutsche Telekom

เดิมที การแก้ไข GNSS ที่แม่นยำนั้นใช้เทคนิคจลนศาสตร์แบบเรียลไทม์ (RTK) ซึ่งต้องใช้สถานีรับสัญญาณดาวเทียมอ้างอิงความหนาแน่นสูง ซึ่งสามารถทนต่อความคลาดเคลื่อนที่จำกัด การเป็นพันธมิตรกับ Swift ทำให้ KDDI สามารถใช้โซลูชันการแก้ไขเป็นพื้นที่กว้างที่จดสิทธิบัตรของ Swift ซึ่งเป็นการผสมผสานของการระบุตำแหน่งความแม่นยำสูง (PPP) และ RTK โซลูชันนี้จะนำเสนอการแก้ไขเป็นพื้นที่กว้าง ด้วยสถานีอ้างอิงความหนาแน่นต่ำ การรวมที่รวดเร็ว ความแม่นยำระดับเซนติเมตร ทั้งหมดนี้จากบริการที่น่าเชื่อถือสูงที่นำเสนอได้อย่างราบรื่นผ่านระบบคลาวด์

ความแม่นยำระดับนั้นที่ก่อนหน้านี้อาจเป็นประโยชน์ต่ออุปกรณ์ในไซต์งาน หรือในภาคสนามเพียงไม่กี่ชนิด ในตอนนี้สามารถเข้าถึงได้โดยผู้ใช้นับล้านจากทุกทวีป ความแม่นยำของบริการระบุตำแหน่งที่เที่ยงตรงของ Skylark ช่วยให้สามารถระบุตำแหน่งระดับเลนได้อย่างรวดเร็ว เพื่อความปลอดภัย ความน่าเชื่อถือ ความถูกต้อง และความพร้อมใช้งานตามความต้องการของระบบอัตโนมัติ แอปพลิเคชันตลาดมวลชนและมือถือ Skylark เป็น GNSS ที่ไม่ขึ้นกับฮาร์ดแวร์ ทำให้ลูกค้ามีทางเลือกในการใช้เซ็นเซอร์ GNSS และช่วยให้ผู้ใช้ในอุตสาหกรรมต่างๆ ได้รับประโยชน์จากความแม่นยำที่สูงขึ้นเพียงแค่สมัครเป็นสมาชิก Skylark การเข้าถึงที่ง่ายและเอาต์พุตที่แม่นยำสูงขึ้นมีประโยชน์สำหรับอุตสาหกรรมต่างๆ ผู้ผลิตยานยนต์สามารถได้ความแม่นยำระดับเลนในชุดเซ็นเซอร์ความถูกต้องสูง การปรับแต่งเส้นทางนั้นช่วยเพิ่มประสิทธิภาพการดำเนินงานและประหยัดต้นทุนให้บริษัทจัดส่งของต่างๆ บริษัทแอปพลิเคชันมือถือปรับปรุงการวิเคราะห์โดยใช้ข้อมูลที่แม่นยำเพื่อสร้างแผนที่ที่ดีขึ้นและแอปที่มีประสิทธิภาพสูงขึ้น การใช้งานในอุตสาหกรรมช่วยให้อุปกรณ์ทำงานเป็นอัตโนมัติ และเพิ่มประสิทธิภาพด้วยการระบุตำแหน่งที่แม่นยำและเชื่อถือได้

“Swift Navigation มีความยินดีที่ได้เป็นพันธมิตรกับ KDDI เพื่อขยายการระบุตำแหน่งที่แม่นยำของ Skylark ในญี่ปุ่นและให้ประโยชน์แก่ลูกค้าทั่วโลก” Timothy Harris ผู้ร่วมก่อตั้งและ CEO ของ Swift Navigation กล่าว “KDDI เป็นผู้นำในการนำเสนอโซลูชันเทคโนโลยีอันล้ำสมัยแก่ลูกค้ามาโดยตลอด และ Swift ยินดีที่จะเพิ่มคุณค่าให้กับธุรกิจของตนผ่านความแม่นยำที่เชื่อถือจาก Skylark”

“เราเชื่อว่าโซลูชันระบุตำแหน่งความแม่นยำสูงของ Swift จะช่วยเพิ่มขีดความสามารถทางธุรกิจของเราในด้านความคล่องตัว และมีส่วนช่วยขยายขอบเขตธุรกิจไปยังยานพาหนะอัจฉริยะ” Hiromichi Matsuda เจ้าหน้าที่บริหาร สำรวจและพัฒนาธุรกิจที่ KDDI CORPORATION กล่าว “ความแม่นยำที่ได้จากการระบุตำแหน่งที่แม่นยำช่วยให้โอกาสสำหรับธุรกิจและอุตสาหกรรมต่างๆ มากมาย และเพิ่มมูลค่าให้กับลูกค้าของเราในญี่ปุ่น”

หากต้องการเรียนรู้เพิ่มเติมเกี่ยวกับวิธีการผสานรวมโซลูชันของ Swift และ KDDI เข้ากับแอปพลิเคชันของคุณได้อย่างง่ายดาย โปรดไปที่ swiftnav.com/kddi

เกี่ยวกับ SWIFT NAVIGATION

Swift Navigation นำเสนอโซลูชันระบุตำแหน่งที่แม่นยำสำหรับยานยนต์ ยานยนต์อัตโนมัติ แอปพลิเคชันมือถือและตลาดมวลชน โดยเริ่มต้นจากเครื่องรับสัญญาณจลนศาสตร์แบบเรียลไทม์ (RTK) ราคาถูก ความแม่นยำสูงรุ่นแรกของอุตสาหกรรม GNSS ซึ่งได้พัฒนาเป็นระบบนิเวศ Swift Navigation ของโซลูชันระบุตำแหน่งสำหรับแอปพลิเคชันที่ทำงานอัตโนมัติ จากบริการระบุตำแหน่งที่แม่นยำของ GNSS ระดับทวีปที่ให้บริการจากระบบคลาวด์โดย Skylark™ โซลูชันซอฟต์แวร์แบบบูรณาการที่ไม่ขึ้นกับฮาร์ดแวร์ Starling® ที่เป็นเครื่องมือระบุตำแหน่ง ไปจนถึงเครื่องรับสัญญาณ Piksi® Multi ที่มีความแม่นยำในระดับเซนติเมตร Duro® และ Duro Inertial RTK ที่ทนทาน Swift Navigation กำลังจะช่วยให้ยานยนต์อัตโนมัติแห่งอนาคตสามารถนำทางและเข้าใจโลกได้ เรียนรู้เพิ่มเติมแบบออนไลน์ได้ที่ swiftnav.com ติดตาม Swift บน Twitter @Swiftnav

เกี่ยวกับ KDDI

KDDI เป็นผู้ให้บริการโทรคมนาคมในประเทศญี่ปุ่น ที่ให้บริการทั้งการสื่อสารแบบโทรศัพท์เคลื่อนที่และแบบโทรศัพท์พื้นฐาน ด้วยฐานลูกค้าที่มั่นคงกว่า 58 ล้านราย และบริการมือถือและร้านค้าที่นำเสนอแบรนด์ “au” KDDI กำลังขยายบริการสู่ธุรกิจ “ออกแบบชีวิต (Life Design)” ซึ่งรวมถึงอีคอมเมิร์ซ ฟินเทค บริการสาธารณูปโภคพลังงานไฟฟ้าทั่วประเทศ ความบันเทิงและการศึกษา KDDI มีประวัติความเป็นมา 60 ปี และปัจจุบันมุ่งเน้นที่การสร้างโครงสร้างพื้นฐานอัจฉริยะผ่านเทคโนโลยี IoT และนวัตกรรมแบบเปิด ร่วมกับพันธมิตรและบริษัทสตาร์ทอัพในหลากหลายอุตสาหกรรม KDDI กำลังเร่งการเติบโตของธุรกิจผู้บริโภคด้านโทรคมนาคมทั่วโลก โดยมีการดำเนินธุรกิจในเมียนมาร์และมองโกเลีย และในธุรกิจไอซีทีระดับโลกภายใต้แบรนด์ “TELEHOUSE”

ติดต่อสื่อประชาสัมพันธ์:
Swift Navigation
[email protected]

Publication relating to a transparency notification

PRESS RELEASE
REGULATED INFORMATION

Publication relating to a transparency notification

Mont-Saint-Guibert (Belgium), July 19, 2021, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

On July 16, 2021, Nyxoah received a transparency notification from BNP Paribas Asset Management SA following the passive downward crossing of the lowest threshold on July 7, 2021. As of such date, BNP Paribas Asset Management SA (through its affiliate BNP Paribas Asset Management France SAS) held 696,562 shares, representing 2.79% of the total number of voting rights on July 7, 2021 (25,002,609).

The notification dated July 16, 2021 contains the following information:

  • Reason for the notification: passive crossing of a threshold; downward crossing of the lowest threshold
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement: BNP Paribas Asset Management SA (with address at SA 47000-75318 Parias cedex 09-France)
  • Date on which the threshold was crossed: July 7, 2021
  • Threshold that is crossed: 3%
  • Denominator: 25,002,609
  • Notified details:
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities
Linked to securities Not linked to the
securities
BNP Paribas Asset Management SA 0 0 0 0.00% 0.00%
BNP Paribas Asset Management France SAS 134,907 696,562 0 2.79% 0.00%
BNP Paribas Asset Management UK Ltd 529,473 0 0 0.00% 0.00%
Subtotal 664,380 696,562 2.79%
TOTAL 696,562 2.79%
  • Chain of controlled undertakings through which the holding is effectively held: BNP Paribas Asset Management France SAS and BNP Paribas Asset Management UK Ltd are controlled by BNP Paribas Asset Management SA, which in turn is controlled by BNP Paribas SA which benefits from the exemption to aggregate its participations with the participations of its subsidiaries that are investment companies, in accordance with article 21 paragraph 2 of the Royal Decree of 14 February 2008 on the disclosure of large shareholdings.
  • Additional information: BNP Paribas Asset Management France SAS is an investment company that exercises voting rights in a discretionary way.

Contact:

Nyxoah
Fabian Suarez, Chief Financial Officer
[email protected]
+32 10 22 24 55

Attachment